Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEMBOV: Pembrolizumab Combinations in Platinum-Resistant Ovarian Cancer
NCT03596281Phase 1Completed
- Sponsor
- Gustave Roussy
- Start
- Dec 2018
- Primary completion
- Mar 2021
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of pembrolizumab in Epithelial Ovarian Cancer (EOC), fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (3 arms), sponsored by Gustave Roussy. Primary endpoint: Dose Limiting Toxicity at 3 weeks. Started Dec 2018; status: completed.
02
Drugs
03
Conditions
Epithelial Ovarian Cancer (EOC)fallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT03596281.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03596281.